Katie Amberg-Johnson

A team-oriented and enthusiastic drug discovery biologist. Broad interests in multiple disease areas, with experience spanning oncology, immunology, liver disease, and infectious disease.

Papers

Predicting resistance to small molecule kinase inhibitors

Nagarajan A, Amberg-Johnson K, Paull E, Huang K, Ghanakota P, Chandrasinghe A, et al. (2024). ChemRxiv. doi:10.26434/chemrxiv-2024-q2v3l (This is a preprint and in submission for peer-review.)

Full Article

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform

Igawa H, Konst ZA, Therrien E, Shelley M, Koldsø H, Bos PH, Negri A, Verras A, Guo J, Dahlgren MK, Levinson A, Parr BT, Kurhade SE, Latthe P, Shetty R, Santhanakrishnan S, Amberg-Johnson K, Futran AS, Atsriku C, Pelletier RD, Liu Z, Bell JA, Bhat S, Svensson M, Gerasyuto AI. (2024). J Med Chem. 2024 Dec 26;67(24):21811-21840. doi: 10.1021/acs.jmedchem.4c01405. Epub 2024 Dec 12. PMID: 39666597.

Full Article

Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity.

Futran AS, Lu T, Amberg-Johnson K, et al. (2024). iScience. 2024;27(5):109693. doi:10.1016/j.isci.2024.109693

Full Article

A mutagenesis screen for essential plastid biogenesis genes in human malaria parasites

Tang, Y., Meister, T. R., Walczak, M., Pulkoski-Gross, M. J., Hari, S. B., Sauer, R. T., Amberg-Johnson, K., & Yeh, E. (2019) PLoS biology, 17(2).

Full Article

Host cell metabolism contributes to delayed-death kinetics of apicoplast inhibitors in Toxoplasma gondii

Amberg-Johnson, K., & Yeh, E. (2019). Antimicrob Agents Chemother. 2019 Jan 29; 63(2)

Full Article

The Toxoplasma gondii Active Serine Hydrolase 4 regulates parasite division and intravacuolar parasite architecture

Foe, IT., Onguka, O., Amberg-Johnson, K., Garner, R., Amara, N., Beatty, W., Yeh, E., Bogyo, M., mSphere. (2018).

Full Article

See all 9 papers

Projects

Predicting resistance to small molecule kinase inhibitors 2025

We report on a physics-based computationally driven lead identification approach that identified structurally unique imidazo pyrazoles as reversible and wild-type-sparing EGFR TKIs of classical mutations.

drug resistance computational prediction EGFR

Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity. 2024

We describe the discovery of potent and specific USP7 inhibitors exemplified by FX1-5303.

acute myeloid leukemia USP7 p53 mechanism-of-action

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform 2024

We report on a physics-based computationally driven lead identification approach that identified structurally unique imidazo pyrazoles as reversible and wild-type-sparing EGFR TKIs of classical mutations

non-small cell lung cancer EGFR drug discovery